Quote:

---

“We look forward to progressing with this key pharmaceutical development with these patent publications leading the way” says Anna Gluskin, EastGate’s CEO. “Lorazepam oral spray, based on our proprietary delivery technology, can be groundbreaking in the anti-seizure market where a fast and effective treatment can be applied by any patient or caregiver resulting in a positive therapeutic impact” continues Gluskin.

---